![]() | |
![]() Above: levocabastine molecular structure Below: 3D representation of levocabastine molecule | |
Clinical data | |
---|---|
Trade names | Livostin |
AHFS/Drugs.com | Micromedex Detailed Consumer Information |
Pregnancy category |
|
Routes of administration | Ophthalmic, intranasal [1] |
ATC code | |
Legal status | |
Legal status | |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C26H29FN2O2 |
Molar mass | 420.528 g·mol−1 |
3D model (JSmol) | |
| |
| |
![]() ![]() |
Levocabastine (trade name Livostin or Livocab, depending on the region) is a selective second-generation H1 receptor antagonist which was discovered at Janssen Pharmaceutica in 1979. It is used for allergic conjunctivitis. [3]
As well as acting as an antihistamine, levocabastine has also subsequently been found to act as a potent and selective antagonist for the neurotensin receptor NTS2, and was the first drug used to characterise the different neurotensin subtypes. [4] [5] This has made it a useful tool for the study of this receptor. [6] [7] [8] [9] [10]
The pharmaceutical drug Bilina is a combination of Levocabastine, benzalkonium chloride, and other components and is typically used in a 0.5 mg/ml suspension as eye-drops, dispensed in 4ml bottles for the treatment of allergic conjunctivitis or similar allergic ocular conditions. Another formulation is available as a nasal spray for the management of allergic rhinitis. [11] [12]